Thursday, 19 April 2018 - 10:38
  • it
  • de
  • en
  • fr


Biogen to pay $600m for Pfizer-developed schizophrenia therapy

Biogen yesterday announced it has acquired from Pfizer the rights to the investigational PF-04958242 therapy, developed to treat some symptoms of schizophrenia, a condition affecting over 20 million people globally. As part of the agreement, Biogen will make Pfizer an…